RPG Life Sciences to deploy ₹500 crore on manufacturing expansion

RPG Life Sciences is accelerating its expansion strategy with plans to deploy ₹500 crore in the coming year towards strategic acquisitions and manufacturing infrastructure, managing director Ashok Nair said. The drug manufacturer has already committed ₹200 crore towards acquisitions and is actively evaluating additional assets to strengthen its production footprint across domestic and international markets.

The company has earmarked a total of ₹700 crore for its expansion phase, with the remaining ₹500 crore to be deployed over the next 12 months to enhance both its formulations and active pharmaceutical ingredients capabilities. "We are actively pursuing good assets that can strengthen our manufacturing footprint," Nair said.

RPG Life Sciences has set an ambitious revenue target of ₹2,000 crore to ₹2,500 crore by 2030, underpinned by strong near-term momentum. In the first quarter of the current financial year, the company achieved 16 per cent revenue growth and 18 per cent earnings before interest, tax, depreciation and amortisation growth, indicating a robust start to the fiscal year.

The expansion comes as Indian pharmaceutical companies increasingly focus on backward integration and manufacturing consolidation to improve margins and reduce dependency on imports. RPG Life Sciences' strategic acquisitions are aligned with the broader industry trend of building self-reliant supply chains for critical pharmaceutical inputs.